Erratum: Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial (J Clin Endocrinol Metab. (2015) 100: 4 (1699-708) DOI: 10.1210/jc.2014-4113;Safety and efficacy of oral octreotide in acromegaly: Results of a multicenter phase III trial

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 4, 2015, Pages 1699-1708

  Melmed, Shlomo ^a   Popovic, Vera ^b   Bidlingmaier, Martin ^c   Mercado, Moises ^d   Van Der Lely, Aart Jan ^e   Biermasz, Nienke ^f   Bolanowski, Marek ^g   Coculescu, Mihail ^h   Schopohl, Jochen ^c   Racz, Karoly ⁱ   Glaser, Benjamin ^j   Goth, Miklos ^k   Greenman, Yona ^l   Trainer, Peter ^m   Mezosi, Emese ⁿ   Shimon, Ilan ^o   Giustina, Andrea ^p   Korbonits, Márta ^q   Bronstein, Marcello D ^r   Kleinberg, David ^s   Teichman, Sam ^t   Gliko Kabir, Irit ^t   Mamluk, Roni ^t   Haviv, Asi ^t   Strasburger, Christian ^u   more..

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b CLINICAL CENTER OF SERBIA   (Serbia)

^c UNIVERSITY OF MUNICH   (Germany)

^d AMERICAN BRITISH COWDRAY MEDICAL CENTER   (Mexico)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g WROCLAW MEDICAL UNIVERSITY   (Poland)

^h C I PARHON NATIONAL INSTITUTE OF ENDOCRINOLOGY   (Romania)

ⁱ SEMMELWEIS UNIVERSITY   (Hungary)

^j HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^k State Health Center   (Hungary)

^l TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^m CHRISTIE HOSPITAL   (United Kingdom)

ⁿ UNIVERSITY OF PÉCS   (Hungary)

^o RABIN MEDICAL CENTER   (Israel)

^p UNIVERSITY OF BRESCIA   (Italy)

^q QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^r UNIVERSITY OF SÃO PAULO   (Brazil)

^s NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^t Chiasma   (United States)

^u CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; CABERGOLINE; GROWTH HORMONE; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACROMEGALY; ADULT; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; CHOLELITHIASIS; CHOLESTASIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FLATULENCE; GASTROINTESTINAL INFECTION; GROWTH HORMONE BLOOD LEVEL; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPOGLYCEMIA; JAUNDICE; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SWEATING; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME; VIRAL GASTROENTERITIS; VOMITING; ADENOMA; AGED; CLINICAL TRIAL; DOSE RESPONSE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ACROMEGALY; ADENOMA; ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; TREATMENT OUTCOME;

EID: 84927612862     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2016-4113     Document Type: Erratum

References (42)

1. Melmed S. Medical progress: acromegaly. NEngl J Med. 2006;355:2558-2573.
2. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25:102-152.
3. Ribeiro-Oliveira A Jr, Barkan A. The changing face of acromegaly-advances in diagnosis and treatment. Nat Rev Endocrinol. 2012;8:605-611.
4. Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol. 2008;159:89-95.
5. Sherlock M, Reulen RC, Aragon-Alonso A, et al. A paradigm shift in the monitoring of patients with acromegaly: last available growth hormone may overestimate risk. J Clin Endocrinol Metab. 2014;99:478-485.
6. Burgers AM, Biermasz NR, Schoones JW, et al. Meta-analysis and dose-response metaregression: circulating insulin-like growth factor I (IGF-I) and mortality. J Clin Endocrinol Metab. 2011;96:2912-2920.
7. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab. 2004;89:1613-1617.
8. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab. 2008;93:61-67.
9. Jane JA Jr, Starke RM, Elzoghby MA, et al. Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome. J Clin Endocrinol Metab. 2011;96:2732-2740.
10. Lee CC, Vance ML, Xu Z, et al. Stereotactic radiosurgery for acromegaly. J Clin Endocrinol Metab. 2014;99:1273-1281.
11. van der Lely AJ, Biller BM, Brue T, et al. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab. 2012;97:1589-1597.
12. Sherlock M, Woods C, Sheppard MC. Medical therapy in acromegaly. Nat Rev Endocrinol. 2011;7:291-300.
13. Giustina A, Chanson P, Kleinberg D, et al. Expert consensus document: a consensus on the medical treatment of acromegaly. Nat Rev Endocrinol. 2014;10:243-248.
14. Marko NF, LaSota E, Hamrahian AH, Weil RJ. Comparative effectiveness review of treatment options for pituitary microadenomas in acromegaly. J Neurosurg. 2012;117:522-538.
15. Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest. 2009;119:3189-3202.
16. Lamberts SW, Uitterlinden P, Verschoor L, van Dongen KJ, del Pozo E. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med. 1985;313:1576-1580.
17. Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD, Melmed S. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest. 1997;100:2386-2392.
18. Bauer W, Briner U, Doepfner W, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 1982;31:1133-1140.
19. Lamberts SW, Oosterom R, Neufeld M, del Pozo E. The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab. 1985;60:1161-1165.
20. Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2002;87:3013-3018.
21. Lancranjan I, Bruns C, Grass P, et al. Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients. Metabolism. 1996;45:67-71.
22. Ho KY, Weissberger AJ, Marbach P, Lazarus L. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety. Ann Intern Med. 1990;112:173-181.
23. Chanson P, Borson-Chazot F, Kuhn JM, et al. Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clin Endocrinol (Oxf). 2008;69:299-305.
24. Murray RD, Kim K, Ren SG, Chelly M, Umehara Y, Melmed S. Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. J Clin Invest. 2004;114:349-356.
25. Pokrajac A, Frystyk J, Flyvbjerg A, Trainer PJ. Pituitary-independent effect of octreotide on IGF1 generation. Eur J Endocrinol. 2009;160:543-548.
26. Maggio ET, Grasso P. Oral delivery of octreotide acetate in Intravail improves uptake, half-life, and bioavailability over subcutaneous administration in male Swiss webster mice. Regul Pept. 2011;167:233-238.
27. Williams G, Ball JA, Burrin JM, Joplin GF, Bloom SR. Effective and lasting growth-hormone suppression in active acromegaly with oral administration of somatostatin analogue SMS 201-995. Lancet. 1986;2:774-778.
28. Tuvia S, Pelled D, Marom K, et al. A novel suspension formulation enhances intestinal absorption of macromolecules via transient and reversible transport mechanisms. Pharm Res. 2014;31:2010-2021.
29. Tuvia S, Atsmon J, Teichman SL, et al. Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J Clin Endocrinol Metab. 2012;97:2362-2369.
30. Bidlingmaier M, Friedrich N, Emeny RT, et al. Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J Clin Endocrinol Metab. 2014;99:1712-1721.
31. Manolopoulou J, Alami Y, Petersenn S, et al. Automated 22-kD growth hormone-specific assay without interference from pegvisomant. Clin Chem. 2012;58:1446-1456.
32. Chieffo C, Cook D, Xiang Q, Frohman LA. Efficacy and safety of an octreotide implant in the treatment of patients with acromegaly. J Clin Endocrinol Metab. 2013;98:4047-4054.
33. Cozzi R, Montini M, Attanasio R, et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab. 2006;91:1397-1403.
34. Stewart PM, Stewart SE, Clark PM, Sheppard MC. Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR). Clin Endocrinol (Oxf). 1999;50:295-299.
35. Biermasz NR, van den Oever NC, Frölich M, et al. Sandostat in LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval. Clin Endocrinol (Oxf). 2003;58:288-295.
36. Wass JA. Octreotide treatment of acromegaly. Horm Res. 1990;33(suppl 1):1-5; discussion 6.
37. Fleseriu M. Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review. Pituitary. 2011;14:184-193.
38. Turner HE, Thornton-Jones VA, Wass JA. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly. Clin Endocrinol (Oxf). 2004;61:224-231.
39. Barkan AL, Beitins IZ, Kelch RP. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol Metab. 1988;67:69-73.
40. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev. 1998;19:717-797.
41. Reutens AT, Hoffman DM, Leung KC, Ho KK. Evaluation and application of a highly sensitive assay for serum growth hormone (GH) in the study of adult GH deficiency. J Clin Endocrinol Metab. 1995;80:480-485.
42. Clemmons DR. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin Chem. 2011;57:555-559.